


High-Risk, Early Breast Cancer: Identifying Patients at a High Risk of Recurrence – Case Studies

Early breast cancer (EBC) recurrence

It is important to identify the patients at a high risk of recurrence so adjuvant therapy can be optimized

Patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) EBC at a high risk of recurrence may present with




≥4 positive axillary lymph nodes (ALNs)

or 1-3 positive ALNs with



Grade 3 disease

or



Tumor size ≥5 cm



Patient Case 1
Samantha

Age and menopausal status	Occupation	Marital status	Presentation	Comorbidities
Aged 52 years, perimenopausal (irregular menses in the past 7 months)	Supervisor at retail store	Divorced with 1 adult child	Presents with right breast nodule discovered during a mammogram test; patient has not had a routine checkup in 3 years	None relevant


Immunohistochemistry profile

ER **85%** PgR **80%** HER2- IHC 0


No clinical or radiographic evidence of distant metastases

Mammography, ultrasound, biopsy, and clinical examination


4 Positive ALNs



Right breast nodule, size 6.5 cm



Invasive ductal carcinoma, grade 3



Diagnosis ▶

Samantha is diagnosed with stage IIIB (T4N2M0) HR+/HER2- breast cancer and is at a **high risk of recurrence** during treatment with adjuvant therapy



Patient Case 2
Clara

Age and menopausal status	Occupation	Marital status	Presentation	Comorbidities
Aged 50 years, postmenopausal	Tax firm executive	Married with 2 adult children	Presents with right breast nodule discovered during magnetic resonance imaging after sports injury	Type 2 diabetes


Immunohistochemistry profile

ER **75%** PgR **95%** HER2- IHC 0


No clinical or radiographic evidence of distant metastases

Mammography, ultrasound, biopsy, and clinical examination


1 Positive ALN



Right breast nodule, size 4 cm



Invasive ductal carcinoma, grade 3



Diagnosis ▶

Clara is diagnosed with stage IIB (T2N1M0) HR+/HER2- breast cancer and is at a **high risk of recurrence** during treatment with adjuvant therapy

Both patient cases are hypothetical.

ER, estrogen receptor; IHC, immunohistochemistry; PgR, progesterone receptor.

Sheffield KM, et al. *Future Oncol.* 2022;18(21): 2667-2682.